Check for updates

#### **OPEN ACCESS**

EDITED BY Anna Bersano, IRCCS Carlo Besta Neurological Institute Foundation, Italy

REVIEWED BY Umesh Kumar, University of Innsbruck, Austria Abhilasha Shiv Chandra Singh, Massachusetts General Hospital and Harvard Medical School, United States Shihua Shi, ETH Zürich, Switzerland Shravan Sivakumar,

Beth Israel Lahey Health, United States \*CORRESPONDENCE

Zuwei Xia ⊠ 935307333@qq.com Dengliang Liu ⊠ 13340210482@163.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

RECEIVED 04 December 2024 ACCEPTED 10 June 2025 PUBLISHED 01 July 2025

#### CITATION

Zheng W, Wang Y, Xia Z and Liu D (2025) Serum ferritin and risk of stroke: a meta-analysis of observation studies. *Front. Neurol.* 16:1539407. doi: 10.3389/fneur.2025.1539407

#### COPYRIGHT

© 2025 Zheng, Wang, Xia and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Serum ferritin and risk of stroke: a meta-analysis of observation studies

# Wen Zheng<sup>1†</sup>, Yangyang Wang<sup>2†</sup>, Zuwei Xia<sup>3</sup>\* and Dengliang Liu<sup>3,4</sup>\*

<sup>1</sup>School of Preclinical Medicine, Zunyi Medical University, Zunyi, China, <sup>2</sup>Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China, <sup>3</sup>Department of Gastrointestinal Surgery, Chongqing Jiulongpo People's Hospital, Chongqing, China, <sup>4</sup>Department of General Surgery, Xipeng Town Health Center of Jiulongpo District, Chongqing, China

**Background and purpose:** Serum ferritin, a well-established biomarker of iron status, has been inconsistently linked to stroke risk in previous studies. This meta-analysis aims to systematically evaluate the association between serum ferritin levels and the risk of stroke.

**Methods:** We conducted a systematic literature search across the PubMed and Embase databases to identify relevant studies. Studies meeting predefined eligibility criteria were selected, and relevant data were extracted. Statistical analysis was performed using Stata 12.0.

**Results:** Ten studies, including eight longitudinal and three cross-sectional, were included in our meta-analysis. Cross-sectional studies showed that stroke patients had significantly higher serum ferritin levels than controls. Longitudinal studies suggested a 22% increase in stroke risk in individuals with higher serum ferritin. Subgroup analysis indicated that further high-quality population-based cohort studies are warranted to validate these findings. Dose–response meta-analysis confirmed a positive association between serum ferritin levels and stroke risk.

**Conclusion:** This meta-analysis provides evidence of a positive association between increased serum ferritin levels and stroke incidence. While these results are promising, definitive conclusions cannot be drawn at this time. Therefore, additional robust, prospective cohort studies are imperative to substantiate this relationship.

KEYWORDS

serum ferritin, stroke, meta-analysis, cerebrovascular accident, iron

#### Introduction

Stroke is a serious cerebrovascular disease. Current data indicates that approximately 12 million people suffer strokes annually, making it one of the most lethal diseases worldwide (1, 2). Although advances in active thrombolytic therapy and surgical interventions have substantially decreased stroke-related mortality, the persistently high incidence of disability and long-term sequelae renders stroke a profoundly debilitating disorder. As a result, preventive strategies have emerged as a paramount focus in stroke management.

Iron is a vital element for human health; however, high concentrations of iron can induce severe cytotoxicity via the Fenton reaction. Furthermore, iron status is closely linked to cardiovascular disease (3–7). Serum ferritin, a key indicator of iron storage/iron level,

indirectly reflects whether an individual is experiencing iron deficiency or overload (8–10). This suggests that serum ferritin levels can serve as a proxy for overall health to some extent. However, observational studies have yielded inconsistent findings regarding the association between serum ferritin and stroke risk (11–19). To clarify this relationship, a meta-analysis was conducted aimed at evaluating the quantitative association between serum ferritin levels and the risk of stroke.

#### **Methods**

The review was conducted in accordance with the PRISMA guidelines and was prospectively registered with the PROSPERO database of systematic reviews (CRD42024628065).

#### Literature search

Literature concerning ferritin and stroke was systematically searched using the PubMed and Embase databases. Two thematic categories were combined with the Boolean operator "AND". The search incorporated the following terms: Ferritins, Iron, Stroke, Cerebrovascular Disorders, Cerebral Hemorrhage, Cerebral Infarction, Subarachnoid Hemorrhage.

#### Inclusion and exclusion criteria

Literature was included as the following criteria: (1) Studies were included if they provided data on or allowed for the estimation of the association between serum ferritin levels and stroke. (2) Studies were included if they reported risk ratios (RRs) or odds ratios (ORs) with their corresponding 95% confidence intervals (CIs), or if these could be calculated from the reported data. (3) In the longitudinal studies, serum ferritin levels were at minimum categorized into high-level and low-level groups. Literature met following criteria were excluded: (1) Meeting abstracts were excluded due to insufficient data available online. (2) In cases where studies utilized the same participant population cohort, the study with the largest sample size was included, and other studies from this population cohort were excluded. (3) Studies were excluded if they presented stroke data as part of total cardiovascular disease data, without providing sufficient detailed information specific to stroke.

#### Literature quality assessment

Newcastle–Ottawa Quality Assessment Scale (NOS) was used to assess the literature quality. Literature with score equal to 9 were regarded as high quality, otherwise, a score lower than 9 is low quality. The detailed data are supplied in Supplementary Table S1.

#### Data abstraction

Data were independently extracted by two authors, Zheng and Wang. Any disagreements were resolved through discussion. The data

extraction contents contain the following points: The first author's name, year of publication, sample size, number of cases, mean age at baseline, time of mean follow up, adjusted factors, type of stroke, gender, serum ferritin level and the RRs/ORs. Note on Serum Ferritin Levels: When serum ferritin levels were reported as a range, the average value was estimated assuming a normal distribution.

#### Statistical analysis

Stata 12.0 was used as statistical analysis software. A fixed effects model was the prior, if met  $I^2 > 50\%$ , indicating a large heterogeneity, use the random effect model instead. Then category analysis was performed by the characteristics (Quality of original literature, adjust risk factors, Sex, mean age at baseline, Race) provides in these literatures. For dose response meta-analysis, linear and a cubic spline model were both used to assess the relationship between serum ferritin and stroke risk. And sensitivity analysis was also used to evaluate the reliability of our results. Due to the results are positive or not often affects the publication of the literature, then the Begg test was used for assessment of publication bias.

Statistical analyses were performed using Stata 12.0. A fixedeffects model was initially employed for meta-analysis. However, if significant heterogeneity was detected (I<sup>2</sup> > 50%), a random-effects model was used instead. Subgroup analyses were conducted based on characteristics reported in the included studies, such as study quality, adjusted risk factors, sex, mean age at baseline, and race. For dose– response meta-analysis, a linear and a cubic spline model were applied to investigate the relationship between serum ferritin levels and stroke risk. Sensitivity analyses were performed to evaluate the reliability of our findings. Publication bias was assessed using Begg's test and Egger's test, given that the likelihood of publication can be influenced by the direction of the results.

#### Results

#### Literature search and study characteristics

The literature search process is illustrated in Figure 1. Initially, 1899 records were identified through database searching. After two rounds of meticulous screening, 10 literatures were ultimately included in the meta-analysis (11–18, 20, 21). Among these literatures, three were cross-sectional studies and eight were longitudinal studies. The cross-sectional studies involved 530,625 participants, while the longitudinal studies included 35,720 participants. In the cross-sectional studies, there were 62,178 stroke patients, although one study did not report the number of stroke cases. For longitudinal studies, 1,074 cases were reported. The mean age of participants at baseline ranged from 41 to 64.8 years. The mean follow-up time for longitudinal studies varied from 4.3 to 17 years. Seven studies were conducted in Europe, two in North America, and one in Asia. All detailed information is summarized in Table 1.

#### Results of qualitative analysis

As shown in Figure 2, the pooled odds ratio (OR) for crosssectional studies was 1.25 (95% CI: 1.11, 1.40), with low



heterogeneity ( $I^2 = 29.9\%$ , p = 0.24). A qualitative analysis of longitudinal studies indicated a 22% increased risk of stroke incidence in individuals with high serum ferritin levels (RR = 1.22, 95% CI: 1.03–1.44,  $I^2 = 0\%$ , p = 0.44). Further categorical analyses of longitudinal studies, stratified by study characteristics (quality, adjustment for risk factors, sex, mean age at baseline, and race), yielded inconsistent results, as detailed in Figure 3. Sensitivity analysis (Figure 4) revealed that excluding certain studies resulted in non-significant findings.

#### Dose response meta-analysis

Based on the data provided in the referenced literature, four studies (11–13, 20) were utilized for dose–response meta-analysis. Figure 5 illustrates the quantitative results from longitudinal studies. The cubic spline model analysis suggests an approximate positive correlation between serum ferritin levels and the incidence of stroke (p = 0.1053). The linear quantitative model analysis further revealed that for every 50 ng/mL increase in serum ferritin, the risk of stroke increases by 8% (RR = 1.08, 95% CI 1.01–1.16, p = 0.02). Specifically: A 100 ng/mL increase in serum ferritin corresponds to a 17% increased risk of stroke (RR = 1.17, 95% CI 1.02–1.35); A 150 ng/mL increase corresponds to a 27% increased risk (RR = 1.27, 95% CI 1.03–1.57); A 200 ng/mL increase corresponds to a 38% increased risk (RR = 1.38, 95% CI 1.04–1.83). These findings underscore the

potential stroke risk associated with elevated serum ferritin levels and advocate for monitoring and management strategies in clinical settings.

#### Publication bias

The Begg's test (p = 0.353 > 0.05) and Egger's test (p = 0.248 > 0.05) found no obvious publication bias for this meta-analysis (Supplementary Figure S1).

#### Discussion

As we know, this is the first time that we have evaluated the relationship between serum ferritin and stroke risk through metaanalysis. In this meta-analysis, the results indicated that individuals with high serum ferritin levels may have a higher risk of stroke compared to those with low serum ferritin levels. Furthermore, a dose-response meta-analysis also revealed a positive correlation between serum ferritin and stroke risk. Additionally, the meta-analysis of cross-sectional studies suggested that there may be a close association between serum ferritin and stroke.

Several potential mechanisms underlie this phenomenon. Firstly, numerous clinical studies have demonstrated that serum ferritin levels are closely associated with carotid atherosclerosis, hypertension, diabetes, steatotic liver and other conditions, these

#### TABLE 1 Characteristics of studies of serum ferritin and the risk of stroke.

Author (country)	Year of publication	character of study	Data source	Sample size	No. of total stroke cases (type)	Sex	Location	Mean age at baseline	Mean follow-up years	Adjustment factors
M. P. Hermans et al. (18)	2010	Cross-sectional study	Not Reported	424	16	Only man	Europe	64.8	Not Applicable	Not adjust
Dipender Gill et al. (16)	2018	Cross-sectional study	Not Reported	521,612	652	Men and woman	Europe	Not Reported	Not Applicable	Not adjust
Dong Liu et al. (19)	2021	Cross-sectional study & longitudinal study	China Health and Nutrition Survey	8,589 7,290	Not Reported 128	Men and woman	Asia	Not Reported 51	Not Applicable 6.1	Adjusted for age, gender, BMI, smoking status, drinking status, diabetes, hypertension, and hsCRP
James S. Pankow et al. (17)	2008	Longitudinal study	Atherosclerosis Risk in Communities (ARIC) Study	6,813	245	Men and woman	North America	54.4	15	Not adjust
Vander et al. (11)	2005	Longitudinal study	European Prospective Investigation Into Cancer and Nutrition (EPIC)	1,132	65	Only women	Europe	59	4.3	Adjusted for age, body mass index, alcohol intake, hsCRP, smoking, hypertension, hypercholesterolemia, diabetes, glucose, LDL cholesterol, and HDL-cholesterol
Sotirios Tsimikas et al. (14)	2009	Longitudinal study	Bruneck study cohort	765	Not Reported	Men and woman	Europe	62.7	10	Adjusted for age and sex
Knuiman MW et al. (13)	2003	Longitudinal study	Busselton Health Survey	1,612	118	Men and woman	Oceania	58.5	17	After adjustment for age and other cardiovascular disease risk factors

Zheng et al.

#### TABLE 1 (Continued)

Author (country)	Year of publication	character of study	Data source	Sample size	No. of total stroke cases (type)	Sex	Location	Mean age at baseline	Mean follow-up years	Adjustment factors
Kim Ekblom et al. (15)	2006	Longitudinal study	Västerbotten Intervention Project	6,952	231	Men and woman	Europe	54.9	13	Adjusted for BMI, hypertension, smoking, diabetes, cholesterol, hsCRP, HFE C282Y and HFE H63D.
Obiora Egbuche et al. (20)	2017	Longitudinal study	Jackson Heart Study	4,659	137	Men and woman	North America	54	8	Adjusted for age, sex, body mass index, smoking status, alcohol use within past 12 months, physical activity score, systolic blood pressure, antihypertensive medication use, low density lipoprotein cholesterol, logarithm of triglycerides, lipid lowering medication use status, fatty liver disease, income, and education
Milton Fabian et al. (12)	2022	Longitudinal study	Scottish health surveys	6,497	150	Men and woman	Europe	41	14.1	Adjusted for age, sex/ menopausal status, fibrinogen levels, GGT levels, alcohol intake, smoking, systolic blood pressure, diastolic blood pressure, total cholesterol, HDL cholesterol, body mass index and year of survey

	Cro	oss-sectional study		
Study	Year	Odd ratios(95%CI)	Forest plot	Weight, %
Dipender Gill.et.al	2018	1.18(1.01,1.38)	k≣⊣	58.12
Dong Liu.et.al	2021	1.38(1.14,1.66)	l H <b>M</b> -I	40.1
M. P. Hermans.et.al	2010	0.75(0.30,1.78)	F	1.79
Overall		1.25(1.11,1.40)	· · · · · · · · · · · · · · · · · · ·	100
Test for heterogeneity		$I^2 = 29.9\%, P = 0.24$	F	
			-1 0 1	Log <sub>10</sub> ()
	L	ongitudinal study		
Study	Year	Relative risks(95%CI)		Weight, %
Vander.et.al(women)	2005	1.77(1.03,3.05)	┟╼┥	9.52
Sotirios Tsimikas.et.al	2009	2.20(1.00,4.90)	⊨∎→	4.44
Knuiman MW.et.al	2003	1.43(0.78,2.64)	r <b>⊥</b> ∎⊸i	7.53
Dong Liu.et.al	2022	1.11(0.89,1.39)	121	56.44
Kim Ekblom.et.al(ischemic stroke)	2006	0.80(0.46,1.40)	⊢≣∔	9.06
Kim Ekblom.et.al(hemorrahagic stroke)	2006	1.07(0.17,6.94)	<b>⊢</b> i	0.82
Obiora Egbuche.et.al(men)	2017	4.36(0.55,34.79)	▶ <b></b>	0.65
Obiora Egbuche.et.al(women)	2017	1.06(0.13,8.40)	<b>⊢</b> i	0.65
Milton Fabian.et.al	2022	1.36(0.81,2.27)	µ <b>l≣</b> ⊣i	10.57
James s.Pankow.et.al	2008	0.60(0.01,3.36)	<b>₽</b>	0.33
			i i	
Overall		1.22(1.03,1.44)	•	100
Test for heterogeneity		$I^2 = 0\%, P = 0.44$	F F F F F F F F F F F F F F F F F F F	
			-2 -1 0 1 2	Log <sub>10</sub> ()

FIGURE 2

Forest plot of studies examining the association between serum ferritin and risk of stroke.

Characteristics	Relative risks(95%CI)	$I^2$ %	Р	Forest
Quality of original liter	ature			
NOS = 9	1.19(1.00,1.41)	0	0.48	¦∎⊣
NOS < 9	2.01(0.93,4.33)	0	0.44	. h
Adjust risk factors				l
Adjust RR	1.22(1.03,1.44)	0.054	0.365	<b>₩</b> -1
Crude RR	1.41(1.22,1.63)	0.085	0.389	HEH
Sex				I
men	1.03(0.78,1.36)	0.468	0.153	H H
women	1.07(1.10,1.96)	0	0.753	⊢
Mean age at baseline (ye	ears)			
≥ 55	1.72(1.20,2.47)	0	0.696	; I ⊢ <b>⊞</b> 1
< 55	1.11(0.92,1.34)	0	0.707	′ <b>⊧</b> ∎⊣
Race				
Europe	1.35(1.01,1.79)	0.318	0.21	
Not europe	1.15(0.94,1.42)	0	0.44	. ∔∎⊣
				F
				0 1 2 3 4

Subgroup analyses between serum ferritin and risk of stroke for longitudinal studies.

factors have been established as risk factors for stroke onset. Therefore, we hypothesize that serum ferritin may indirectly reflect stroke occurrence through its association with carotid atherosclerosis, hypertension, diabetes, steatotic liver and other conditions (22-26). Secondly, as a critical indicator of iron homeostasis, serum ferritin levels are markedly elevated in the context of pathological iron excess. Iron overload can generate reactive oxygen species via the Fenton reaction (27, 28), further triggering inflammatory responses, damaging vascular endothelial cells, and increasing the risk of cardiovascular and cerebrovascular





disease (29). Additionally, research has shown that high red meat consumption is linked to cardiovascular diseases (30), and individuals with higher red meat intake typically have elevated serum ferritin levels (31).

Previous meta-analyses have suggested a positive association between ferritin levels and the risk of coronary artery disease (32), given the shared pathophysiology between coronary artery disease and stroke to some extent (As mentioned previously, diseases such as carotid atherosclerosis, hypertension, diabetes, steatotic liver and other conditions), this finding further implies that serum ferritin could serve as a predictive risk factor for stroke occurrence. In our meta-analysis, we pooled three cross-sectional studies, yielding a pooled odds ratio (OR) of 1.25 (95% CI: 1.11, 1.40), with a low level of heterogeneity (I<sup>2</sup> = 29.9%, p = 0.24). While cross-sectional studies cannot establish causality, they do suggest a close relationship between serum ferritin levels and stroke. Moreover, the longitudinal studies included in our meta-analysis offer more robust evidence supporting the role of serum ferritin as a predictive risk factor. Meta-analysis of these longitudinal studies demonstrated a positive correlation between serum ferritin levels and stroke risk (high level serum ferritin vs. low level ferritin, RR = 1.22, 95% CI: 1.03–1.44, I<sup>2</sup> = 0, *p* = 0.44). Consequently, we have reason to believe that serum ferritin can be considered as a valuable indicator for predicting the occurrence of stroke.

While this meta-analysis yielded a positive overall result, certain limitations must be acknowledged. Although the total qualitative analysis was positive, the categorical analysis (based on the quality of original literature, adjustment of risk factors, sex, mean age at baseline, and race) for longitudinal studies revealed several negative findings (Figure 3). Moreover, the sensitivity analysis also produced some negative results. These findings suggest that the robustness of our results should be carefully reconsidered, despite the possibility that the negative results stem from the limited number of studies included in the subgroup analysis. Second, we used the highest and lowest serum ferritin groups in the article to conduct the qualitative analysis, but in some literature, the exact serum ferritin level is indeed unclear (14, 15, 19), potentially contributing to a false positive result. Thirdly, according to the cubic spline model dose-response metaanalysis results, the population with extremely low serum ferritin levels (within the 0 to 100  $\mu$ g/L range) demonstrated a little higher incidence of stroke. Although this finding did not reach statistical significance, several potential explanations warrant consideration. Supporting this, some studies have identified excessively low serum ferritin as a potential risk factor for stroke (11), and a link between iron-deficiency anemia and increased stroke risk has also been reported (33, 34). Therefore, more high-quality cohort studies are needed to determine whether excessively low serum ferritin levels can be used as a reliable predictor of stroke.

# Conclusion

This meta-analysis revealed a positive correlation trend between serum ferritin levels and stroke risk. However, the categorical analysis and sensitivity analysis provided less conclusive results. Therefore, further studies are needed to validate and strengthen our findings.

# Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

#### Author contributions

WZ: Writing – original draft, Data curation, Formal analysis. YW: Data curation, Methodology, Writing – original draft. ZX: Supervision, Writing – review & editing, Project administration. DL: Writing – review & editing, Conceptualization.

#### Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

## References

1. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of disease study 2017. *Lancet.* (2019) 394:1145–58. doi: 10.1016/S0140-6736(19)30427-1

2. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. *Lancet Neurol.* (2021) 20:795–820. doi: 10.1016/S1474-4422(21)00252-0

3. Cornelissen A, Guo L, Sakamoto A, Virmani R, Finn AV. New insights into the role of iron in inflammation and atherosclerosis. *EBioMedicine*. (2019) 47:598–606. doi: 10.1016/j.ebiom.2019.08.014

4. Wunderer F, Traeger L, Sigurslid HH, Meybohm P, Bloch DB, Malhotra R. The role of hepcidin and iron homeostasis in atherosclerosis. *Pharmacol Res.* (2020) 153:104664. doi: 10.1016/j.phrs.2020.104664

5. Winterbourn CC. Toxicity of iron and hydrogen peroxide: the Fenton reaction. *Toxicol Lett.* (1995) 82–83:969–74. doi: 10.1016/0378-4274(95)03532-x

6. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD. Serum transferrin saturation, stroke incidence, and mortality in women and men. The NHANES I epidemiologic Followup study. National Health and nutrition examination survey. Am J Epidemiol. (1996) 144:59–68. doi: 10.1093/oxfordjournals.aje.a008855

7. Corti MC, Gaziano M, Hennekens CH. Iron status and risk of cardiovascular disease. Ann Epidemiol. (1997) 7:62–8. doi: 10.1016/s1047-2797(96)00112-3

8. Daru J, Colman K, Stanworth SJ, De La Salle B, Wood EM, Pasricha SR. Serum ferritin as an indicator of iron status: what do we need to know? *Am J Clin Nutr.* (2017) *106*:1634S–9S. doi: 10.3945/ajcn.117.155960

9. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev. (2009) 23:95–104. doi: 10.1016/j.blre.2008.08.001

10. Garcia-Casal MN, Pasricha SR, Martinez RX, Lopez-Perez L, Pena-Rosas JP. Serum or plasma ferritin concentration as an index of iron deficiency and overload. *Cochrane Database Syst Rev.* (2021) 2021:CD011817. doi: 10.1002/14651858.CD011817.pub2

11. van der AD, Grobbee DE, Roest M, Marx JJ, Voorbij HA, van der Schouw YT. Serum ferritin is a risk factor for stroke in postmenopausal women. *Stroke.* (2005) 36:1637–41. doi: 10.1161/01.STR.0000173172.82880.72

12. Suarez-Ortegon MF, McLachlan S, Fernandez-Real JM, Tuomainen TP, Aregbesola A, Wild SH. Serum ferritin and incident cardiometabolic diseases in Scottish adults. *Cardiovasc Diabetol.* (2022) 21:26. doi: 10.1186/s12933-022-01450-7

#### **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## **Generative AI statement**

The authors declare that no Gen AI was used in the creation of this manuscript.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

#### Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2025.1539407/ full#supplementary-material

13. Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC. Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. *Am J Epidemiol.* (2003) 158:144–9. doi: 10.1093/aje/kwg121

14. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. *Eur Heart J.* (2009) 30:107–15. doi: 10.1093/eurheartj/ehn502

15. Ekblom K, Hultdin J, Stegmayr B, Johansson I, Van Guelpen B, Hallmans G, et al. Iron stores and HFE genotypes are not related to increased risk of ischemic stroke. A prospective nested case-referent study. *Cerebrovasc Dis.* (2007) 24:405–11. doi: 10.1159/000108429

16. Gill D, Monori G, Tzoulaki I, Dehghan A. Iron status and risk of stroke. *Stroke*. (2018) 49:2815–21. doi: 10.1161/STROKEAHA.118.022701

17. Pankow JS, Boerwinkle E, Adams PC, Guallar E, Leiendecker-Foster C, Rogowski J, et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the atherosclerosis risk in communities (ARIC) study. *Transl Res.* (2008) 152:3–10. doi: 10.1016/j.trsl.2008.05.005

18. Hermans MP, Ahn SA, Amoussou-Guenou KD, Balde NM, Rousseau MF. Do high ferritin levels confer lower cardiovascular risk in men with type 2 diabetes? *Diabet Med.* (2010) 27:417–22. doi: 10.1111/j.1464-5491.2010.02979.x

19. Liu D, Zhang Y, Wang CC, Xiao-Hong E, Zuo H. Markers of iron metabolism and stroke risk: cross-sectional and longitudinal findings from the China health and nutrition survey (CHNS). *Iran J Public Health*. (2022) 51:115–23. doi: 10.18502/ijph.v51i1.8302

20. Egbuche O, Millard HR, Renelus B, Maihemuti A, Musani SK, Fox ER, et al. Serum ferritin levels in blacks without known cardiovascular disease (from the Jackson heart study). *Am J Cardiol.* (2017) 120:1533–40. doi: 10.1016/j.amjcard.2017.07.045

21. Luo D, Zhong Z, Qiu Y, Wang Y, Li H, Lin J, et al. Abnormal iron status is associated with an increased risk of mortality in patients on peritoneal dialysis. *Nutr Metab Cardiovasc Dis.* (2021) 31:1148–55. doi: 10.1016/j.numecd.2020.12.018

22. Xu H, Song Y, Xu J, Gu Y, Zhang Q, Liu L, et al. Increased serum ferritin levels are independently associated with carotid atherosclerosis in women. *Br J Nutr.* (2017) 117:1623–30. doi: 10.1017/S0007114517001544

23. Ryoo JH, Kim SY, Oh CM, Park SK, Kim E, Park SJ, et al. The incidental relationship between serum ferritin levels and hypertension. *Int J Cardiol.* (2015) 183:258–62. doi: 10.1016/j.ijcard.2014.10.152

24. Choi B, Yeum KJ, Park SJ, Kim KN, Joo NS. Elevated serum ferritin and mercury concentrations are associated with hypertension; analysis of the fourth and fifth Korea national health and nutrition examination survey (KNHANES IV-2, 3, 2008-2009 and V-1, 2010). *Environ Toxicol.* (2015) 30:101–8. doi: 10.1002/tox.21899

25. Diaz-Lopez A, Iglesias-Vazquez L, Palleja-Millan M, Rey Renones C, Flores Mateo G, Arija V. Association between iron status and incident type 2 diabetes: a population-based cohort study. *Nutrients*. (2020) 12:3249. doi: 10.3390/nu12113249

26. Yan J, Guan T, Guo M, Liu J. Serum ferritin and non-alcoholic fatty liver disease: a meta-analysis and systematic review. *Turk J Gastroenterol.* (2023) 34:952–60. doi: 10.5152/tjg.2023.22453

27. Grant ES, Clucas DB, McColl G, Hall LT, Simpson DA. Re-examining ferritinbound iron: current and developing clinical tools. *Clin Chem Lab Med.* (2021) 59:459–71. doi: 10.1515/cclm-2020-1095

28. Liu K, Huang L, Qi S, Liu S, Xie W, Du L, et al. Ferroptosis: the entanglement between traditional drugs and Nanodrugs in tumor therapy. *Adv Healthc Mater*. (2023) 12:e2203085. doi: 10.1002/adhm.202203085

29. Petrucci G, Rizzi A, Hatem D, Tosti G, Rocca B, Pitocco D. Role of oxidative stress in the pathogenesis of atherothrombotic diseases. *Antioxidants (Basel)*. (2022) 11:1408. doi: 10.3390/antiox11071408

30. Kaluza J, Wolk A, Larsson SC. Red meat consumption and risk of stroke: a meta-analysis of prospective studies. *Stroke*. (2012) 43:2556–60. doi: 10.1161/STROKEAHA.112.663286

31. Quintana Pacheco DA, Sookthai D, Wittenbecher C, Graf ME, Schubel R, Johnson T, et al. Red meat consumption and risk of cardiovascular diseases-is increased iron load a possible link? *Am J Clin Nutr.* (2018) 107:113–9. doi: 10.1093/ajcn/nqx014

32. Zhou Y, Liu T, Tian C, Kang P, Jia C. Association of serum ferritin with coronary artery disease. *Clin Biochem*. (2012) 45:1336–41. doi: 10.1016/j.clinbiochem.2012.06.013

33. Chang YL, Hung SH, Ling W, Lin HC, Li HC, Chung SD. Association between ischemic stroke and iron-deficiency anemia: a population-based study. *PLoS One*. (2013) 8:e82952. doi: 10.1371/journal.pone.0082952

34. Azab SF, Abdelsalam SM, Saleh SH, Elbehedy RM, Lotfy SM, Esh AM, et al. Iron deficiency anemia as a risk factor for cerebrovascular events in early childhood: a case-control study. *Ann Hematol.* (2014) 93:571–6. doi: 10.1007/s00277-013-1922-y